Table 1 Baseline data in nephrotic patients treated with direct oral anticoagulants

Age – years (median, (IQR))

57 (33–62)

51 (31–61)

62 (61–62)

Female sex – n (%)

11 (52)

7 (44)

4 (80)

Preexisting coagulation disorder – n (%)

1 (5)

0 (0)

1 (20)

Autoimmune disease – n (%)

2 (10)

1 (6)

1 (20)

Diabetes – n (%)

1 (5)

1 (6)

0 (0)

Liver disease

0 (0)

0 (0)

0 (0)

Atrial fibrillation

0 (0)

0 (0)

0 (0)

Cancer disease

0 (0)

0 (0)

0 (0)

Preceding thromboembolic event – n (%)

2 (10)

1 (6)

1 (20)

Histological diagnosis – n (%)

 MGN

7 (33)

5 (31)

2 (40)

 FSGS

2 (10)

1 (6)

1 (20)

 MCD

7 (33)

6 (38)

1 (20)

 IgAN

1 (5)

0 (0)

1 (20)

 Amyloidosis

4 (19)

4 (25)

0 (0)

Anticoagulation just prior to DOAC – n (%)

 LMWH

1 (5)

1 (6)

0 (0)

 Concomitant anti-platelet treatment – n (%)

1 (5)

0 (0)

1 (20)

CHA₂DS₂-VASc score, distribution – n (%)

 0

10 (48)

10 (63)

0 (0)

 1

8 (38)

4 (25)

4 (80)

 2

3 (14)

2 (13)

1 (20)

HAS-BLED score, distribution – n (%)

 0

16 (76)

13 (81)

3 (60)

 1

4 (19)

3 (19)

1 (20)

 2

1 (5)

0 (0)

1 (20)

GN-risk-score – n (%)

 Low risk

19 (90)

15 (94)

4 (80)

 Intermediate risk

1 (5)

0 (0)

1 (20)

 High risk

1 (5)

1 (6)

0 (0)